Pruritus Clinical Trial
Official title:
Gabapentin for Prophylaxis Intrathecal Morphine-Induced Pruritus After Orthopedics Surgery
Intrathecal morphine provides good postoperative analgesia for up to 18-24 hour after
administration. Pruritus is the most common side effect of intrathecal morphine, which the
incidence was reported as 20%-100%2 and 63% in Songklanagarind Hospital. Pathophysiology of
opioid-induced pruritus remain unclear and more than one mechanism may be involved in the
development of opioid-induced pruritus, such as, mediated central µ opioid receptors,
Dopamine (D2) receptors, Serotonin (5-HT3) receptors, prostaglandin system, GABA receptors,
and glycine receptors, so that why opioid-induced pruritus is difficult to manage. Many
medications have been used to treat this side effect included antihistamines, 5-HT3
(serotonin) receptor antagonists, opioid antagonists, opioid agonist-antagonists, propofol,
and nonsteroidal antiinflammatory drugs.
Gabapentin is an anticonvulsant, a structural analog of aminobutyric acid, and currently
approved by the Food and Drug Administration for the treatment of partial seizures and
postherpetic neuralgia. Many studies have shown gabapentin to be effective in the case of
brachioradial pruritus, itch of neuropathic in origin, uremic pruritus, multiple
sclerosis-induced pruritus,cholestatic pruritus, itch produced by burn, and pruritus of
unknown origin. However, there is only one small study in Taiwan shown the effectiveness of
gabapentin 1200 mg in prevention of intrathecal morphine-induced pruritus in orthopedic
surgery, which could reduce incidence of pruritus from 77.5% to 47.5% (38.7% reduction).
Because gabapentin has several side effects especially in high dose such as drowsiness, dry
mouth, headache, unsteadiness, reduced co-ordination or slowed reaction, constipation,
diarrhea, peripheral edema, dizziness, confusion, loss of concentration, weight gain, and
nausea, vomiting, so in our study we decided to reduce the dose of gabapentin. Therefore, we
would like to know if gabapentin in a smaller dose (600 mg) used in the wider range of age
including the elderly can decrease the incidence of intrathecal morphine-induced pruritus in
orthopedic surgery in Songklanagarind Hospital.
The study was approved by the ethic committee of Songklanagarind Hospital in Songkhla, Thailand, and was designed as a randomized, double-blind, placebo-controlled trial. All patients gave their informed consent after receiving written information of the study. Orthopedic patients were invited to participated between September 2009 and August 2010. Patients were considered eligible if they were aged between 15-70 yr, ASA physical status I-III, and were scheduled for lower limb surgery under spinal anesthesia. Patients were excluded if they presented of any following reasons: contraindication for spinal anesthesia, known allergy history to gabapentin, complaint of pruritus before surgery, morbid obesity (BMI > 35), coexisting skin disorder, and any systemic disease associated with pruritus. Patients who had history of seizure attacks, mental illness, chronic headache, or neuropathic pain and were concomitantly using of anticonvulsants, antidepressants, antipsychotics, or antihistamine were also excluded. Patients were randomized into the treatment and the placebo groups according to a computer-generated randomization list and patients were allocated consecutively. The blinding was maintained by keeping the treatment code with one of the investigators, separating them from the investigator performing the assessments. Patients in the gabapentin group received two capsules of gabapentin 300 mg (Neurontin®, Pfizer) at 2 h before operation. The patients in the placebo group received equal numbers of identical looking placebo, according to the same schedule. In order to prepare the identical looking medications, for gabapentin group we coated gabapentin capsules by other capsules and for placebo group we filled the identical looking capsules with flour. All patients did not receive any other sedative agents beside the study drugs. After standard monitoring (electrocardiogram, noninvasive arterial blood pressure, and pulse oximetry) was set-up in the operating room, each patient was received Ringer's lactate or normal saline solution 5-10 mL/kg, spinal anesthesia was performed at the L2-3 or L3-4 interspace with a 27-gauge Quincke-type needle using 0.5% isobaric bupivacaine plus 0.2 mg of preservative-free morphine. Midazolam, morphine, fentanyl and propofol were administered intravenously (IV) for intraoperative sedation at the discretion of the anesthesiologist. We excluded the patient who failed spinal block, inadequate block, and the patient who had prolong operative time which had to continue with general anesthesia because we could not evaluate pruritus. The sedation level was evaluated by the Ramsay Sedation Scale during the operation. The patients were followed for 24 h after intrathecal administration of morphine. Postoperative wound pain was assessed with a verbal numeric rating scale (VNRS). Rescue treatments for postoperative pain were provided with any medications ordered by anesthesiologists or orthopedists. Pruritus was evaluated at 1, 2, 3, 4, 6, 9, 12, and 24 h after intrathecal administration of morphine by a blinded investigator. The patients were questioned about the presence and degree of pruritus. The degree of pruritus was classified as 0 = absent, 1 = mild (restricted to one area such as face or arms, not troubling the patient, often reported only after prompting), 2 = moderate (affecting a larger area such as face and arms or face and anterior surface of thorax, not disturbing the patient, therefore not requiring treatment), or 3 = severe (extensive or generalized, often disturbing the patient to the point of necessitating treatment). Severe pruritus was treated with 10 mg IV chlopheniramine. Patients were also evaluated the severity of postoperative nausea and vomiting (PONV) which graded on a four point scale as 0 = no nausea or vomiting, 1 = mild nausea only, 2 = nausea or vomiting responding to initial treatment, and 3 = nausea or vomiting requiring repeat treatment, the presence of urinary retention and the other side effects of drug treatment. Patients who reported vomiting received 4 mg IV ondansetron or 10 mg IV metoclopramide. The primary outcome measure of the study was the incidence of pruritus during the 24 h follow-up period. The difference of onset time and severity of pruritus in the gabapentin and placebo groups served as the secondary outcome measure. Additional secondary outcome measures were side effects of the gabapentin group. There was an intention-to-treat in our study. Statistical analysis was performed using the R 2.11.1 software. We considered a 35% reduction in the incidence of pruritus to be clinically important according to the previous study's result showed that gabapentin 1200 mg could reduce incidence of intrathecal morphine-induce pruritus by 38%12. In our study we reduced the dose of gabapentin to 600 mg as describe previously so we think the efficacy of the drug may decrease so we assumed that gabapentin 600 mg could reduced incidence of intrathecal morphine-induced pruritus by 35%. Power analysis was performed to determine the sample size with a probability for a type II error of 0.2 and type I error of 0.05. To detect a 35% reduction in the incidence of pruritus, using the incidence of pruritus in Songklanagarind Hospital which was 63%, a sample size of 80 patients in each group was estimated to be required. To accommodate for 10% patient dropouts and failure of spinal anesthesia, 88 patients were enrolled in each group. Incidence of pruritus was measured by using Chi-Square test. The onset time and severity of pruritus was analyzed by means of Kaplan-Meier probability curves. Continuous data were analyzed using un-paired student T-test for normal distribution data such as BMI and by Mann-Whitney U test for non normal distribution data such as age, operative time, postoperative verbal numeric rating pain score. Comparison of the categorical data was performed using chi-square test such as incidence of PONV, hypotension, and shivering and by Fisher's exact test if expected value < 5 such as type of operation, incidence of bradycardia, and ASA classification. Results are expressed as mean+SD for normal distribution data and median (range) for non normal distribution. For all determinations, P values of < 0.05 were considered to be statistically significant. ;
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05038982 -
Efficacy of Abrocitinib for Reducing Pruritus in Adults With Prurigo Nodularis and Chronic Pruritus of Unknown Origin
|
Phase 2 | |
Completed |
NCT04510090 -
Evaluate the Safety, Tolerability, and PK of EP547 in Healthy Subjects and Subjects With Cholestatic or Uremic Pruritus
|
Phase 1 | |
Terminated |
NCT01825655 -
Study of Using Long Acting Antihistamine to Treat Opioid Induced Itching
|
Phase 4 | |
Completed |
NCT02143973 -
Open Label Extension Study of Nalbuphine HCl ER in Hemodialysis Patients With Uremic Pruritus
|
Phase 2/Phase 3 | |
Completed |
NCT00782054 -
Evaluation of Post Burn Rehabilitation Population for Itch Control
|
Phase 4 | |
Completed |
NCT04999787 -
A Clinical Trial Evaluating the Efficacy, Safety, and Pharmacokinetics of HSK21542 Injection in Liver Disease Subjects With Pruritus
|
Phase 2 | |
Recruiting |
NCT04256759 -
Dupilumab for the Treatment of Moderate to Severe Chronic Hepatic Pruritus
|
Phase 2 | |
Completed |
NCT04337073 -
The Effect of Propofol on Dexamethasone-induced Perineal Pruritus
|
Early Phase 1 | |
Completed |
NCT04415034 -
Scalp Pruritus Measurement Using Visual Analog Scale and 5-d Itch Scale in Children With Pediculosis Capitis
|
||
Active, not recruiting |
NCT05525520 -
Study to Evaluate EP547 in Subjects With Cholestatic Pruritus Due to Primary Biliary Cholangitis or Primary Sclerosing Cholangitis
|
Phase 2 | |
Recruiting |
NCT03340155 -
Mechanisms of Action of Photo(Chemo)Therapy in Skin Diseases
|
N/A | |
Completed |
NCT04399525 -
Influence of H1-antihistamines on the Dermal Blood Flow Response to Histamine, Cinnamaldehyde and Capsaicin.
|
N/A | |
Recruiting |
NCT02432508 -
Efficacy of Laser Acupuncture on Pruritus in Patients With Chronic Kidney Disease Undergoing Hemodialysis
|
N/A | |
Completed |
NCT02653703 -
L-menthol as a Topical Counter-irritant to TRPA1-induced Neurogenic Inflammation and Pain
|
N/A | |
Completed |
NCT01963793 -
Topical Aprepitant in Prurigo Patients
|
Phase 2 | |
Completed |
NCT01232985 -
Efficacy and Tolerability Study of Device, RD047-26 for the Treatment of Mild to Moderate Atopic Dermatitis in Adults
|
Phase 2 | |
Not yet recruiting |
NCT00577967 -
Gabapentin - A Solution to Uremic Pruritus?
|
N/A | |
Recruiting |
NCT06120907 -
Swiss Itch Registry
|
||
Recruiting |
NCT04589429 -
Adding Nalbuphine for Control of Intrathecal Morphine Pruritus
|
Phase 2 | |
Completed |
NCT03322137 -
Safety, Efficacy, and Tolerability of SNA-120 in Subjects With Pruritus Associated With Psoriasis Vulgaris
|
Phase 2 |